Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, recently announced that the Centers for Medicare & Medicaid ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

Prostate cancer is the second-leading cause of death among American men, killing one in 44. In the United States, 3.3 million men are survivors of prostate cancer, and the risk for developing the ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

Dec. 15, 2025 — For decades, when tests suggested that a man might have prostate cancer, the next step was usually a biopsy. The procedure, where a doctor uses a thin needle to collect prostate ...

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical announced that The Johns Hopkins Hospital has performed its first ...

ISMI offers a radiologist-led Full-Body MRI in Montreal to identify life-saving findings, detect health risks, and support ...